Advertisement

Zunyimycin C inhibits the proliferation of lung cancer cells by inducing apoptosis through an AKT-related mechanism

  • Wei Li
  • Jie Zheng
  • Wenhong Wang
  • Zhongming Qian
  • Yuxin BaoEmail author
Original Research
  • 5 Downloads

Abstract

Objective

Zunyimycin C is a novel halogenated type II polyketide derived from the fermentation product of the Streptomyces species with notable antibiotic activity. However, it is still unclear whether zunyimycin C could inhibit the activity of cancer cells. In this study, human lung adenocarcinoma cell line A549, the large-cell lung cancer cell line NCI-H460 and the non-small-cell lung cancer cell line NCI-H1299 were employed to determine the in vitro anticancer properties of zunyimycin C and underlying molecular mechanisms.

Materials and methods

The cellular viability and proliferative properties of lung cancer cells were investigated using the Cell Counting Kit-8 and colony formation assay, respectively. The mRNA expression of apoptotic genes related to lung cancer was studied using reverse-transcription polymerase chain reaction. The apoptotic ratio was measured through flow cytometry. The protein expression was visualized via western blotting using specific antibodies.

Results

Zunyimycin C could inhibit cell proliferation and induce apoptosis in a dose-dependent manner. The expression levels of apoptosis-related proteins (i.e., BAX, cleaved-caspase-3, and cleaved-caspase-9) were increased compared with the control group. However, the levels of Bcl-2 and phosphorylated AKT were decreased by administration by zunyimycin C.

Conclusions

Collectively, these results implied that zunyimycin C could inhibit cell proliferation and induce apoptosis via AKT phosphorylation.

Keywords

Zunyimycin C Lung cancer Cell proliferation inhibition AKT Apoptosis 

Notes

Acknowledgements

The Authors would like to thank Yun Liu for his assistance with flow cytometry and Sanhua Li for her technical assistance. Especially, thanks to Changwu Yue for providing test compound of zunyimycin C. This work was funded by the National Nature Science Foundation of China (Grant no. 31460006), the Science and Technology Foundation of Guizhou Province (no. (2013) 3013).

Authors’ contributions

Study design: YB. Data acquisition: WL. Data analysis and interpretation: YB, ZQ, and WL. Statistical analysis: WL. Manuscript writing: WL. Manuscript editing: YB, ZQ. Manuscript review: WL, JZ, WW, YB, and ZQ.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. Ahn DS, Lee HJ, Hwang J et al. (2018) Lambertianic acid sensitizes non-small cell lung cancers to TRAIL-induced apoptosis via inhibition of XIAP/NF-κB and activation of caspases and death receptor 4. Int J Mol Sci 19(5):1476Google Scholar
  2. Andreu-Fernández V, Sancho M, Genovés A et al. (2017) Bax transmembrane domain interacts with prosurvival Bcl-2 proteins in biological membranes. Proc Natl Acad Sci USA 114(2):310–315Google Scholar
  3. Byers LA, Rudin CM (2015) Small cell lung cancer: where do we go from here? Cancer 121:664–672Google Scholar
  4. Barka EA, Vatsa P, Sanchez L et al. (2016) Taxonomy, physiology, and natural products of actinobacteria. Microbiol Mol Biol Rev 80(1):1–43Google Scholar
  5. Boichuk S, Lee DJ, Mehalek KR et al. (2014) Unbiased compound screening identifies unexpected drug sensitivities and novel treatment options for gastrointestinal stromal tumors. Cancer Res 74(4):1200–1213Google Scholar
  6. Booth LA, Tavallai S, Hamed HA et al. (2014) The role of cell signalling in the crosstalk between autophagy and apoptosis. Cell Signal 26(3):549–555Google Scholar
  7. Birkinshaw RW, Czabotar PE (2017) The BCL-2 family of proteins and mitochondrial outer membrane permeabilisation. Semin Cell Dev Biol 72:152–162Google Scholar
  8. Chen W, Zheng R, Baade PD et al. (2016) Cancer statistics in China, 2015. Cancer J Clin 66(2):115–132Google Scholar
  9. Chen Y, Tang Q, Xiao Q et al. (2017) Targeting EP4 downstream c-Jun through ERK1/2-mediated reduction of DNMT1 reveals novel mechanism of solamargine inhibited growth of lung cancer cells. J Cell Mol Med 21:222–233Google Scholar
  10. Deben C, Lardon F, Wouters A et al. (2016) APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines. Cancer Lett 375(2):313–322Google Scholar
  11. Fei HR, Tian H, Zhou XL et al. (2016) Inhibition of autophagy enhances effects of PF-04691502 on apoptosis and DNA damage of lung cancer cells. Int J Biochem Cell Biol 78:52–62Google Scholar
  12. Fouillaud M, Venkatachalam M, Girard-Valenciennes E et al. (2016) Anthraquinones and derivatives from marine-derived fungi: structural diversity and selected biological activities. Mar Drugs 14(4):64Google Scholar
  13. Franke TF (2008) PI3K/Akt: getting it right matters. Oncogene 27(50):6473–6488Google Scholar
  14. Guise CP, Mowday AM, Ashoorzadeh A et al. (2014) Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia. Chin J Cancer 33(2):80–86Google Scholar
  15. Hadjithomas M, Chen IA, Chu K et al. (2017) IMG-ABC: new features for bacterial secondary metabolism analysis and targeted biosynthetic gene cluster discovery in thousands of microbial genomes. Nucleic Acids Res 45(D1):D560–D565Google Scholar
  16. Hansakul P, Aree K, Tanuchit S, Itharat A (2014) Growth arrest and apoptosis via caspase activation of dioscoreanone in human non-small-cell lung cancer A549 cells. BMC Complement Altern Med 14:413Google Scholar
  17. Hassan M, Watari H, AbuAlmaaty A et al. (2014) Apoptosis and molecular targeting therapy in cancer. Biomed Res Int 2014:150845Google Scholar
  18. Herman NA, Kim SJ, Li JS et al. (2017) The industrial anaerobe Clostridium acetobutylicum uses polyketides to regulate cellular differentiation. Nat Commun 8(1):1514Google Scholar
  19. Hong QY, Wu GM, Qian GS et al. (2015) Prevention and management of lung cancer in China. Cancer 121:3080–3088Google Scholar
  20. Hua F, Shang S, Hu ZW (2017) Seeking new anti-cancer agents from autophagy-regulating natural products. J Asian Nat Prod Res 19(4):305–313Google Scholar
  21. Jacobsen K, Bertran-Alamillo J, Molina MA et al. (2017) Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. Nat commun 8(1):410Google Scholar
  22. Kang Y, Wang ZJ, Xie D et al. (2017) Characterization and potential antitumor activity of polysaccharide from Gracilariopsis lemaneiformis. Mar Drugs 15(4):100Google Scholar
  23. Kawada M, Kawatsu M, Masuda T et al. (2003) Specific inhibitors of protein phosphatase 2A inhibit tumor metastasis through augmentation of natural killer cells. Int Immunopharmacol 3(2):179–188Google Scholar
  24. Kinghorn AD, DE Blanco EJ, Lucas DM et al. (2016) Discovery of anticancer agents of diverse natural origin. Anticancer Res 36(11):5623–5637Google Scholar
  25. Kodali S, Galgoci A, Young K et al. (2005) Determination of selectivity and efficacy of fatty acid synthesis inhibitors. J Biol Chem 280(2):1669–1677Google Scholar
  26. Lü Y, Shao M, Wang Y et al. (2017) Zunyimycins B and C, new chloroanthrabenzoxocinones antibiotics against methicillin-resistant Staphylococcus aureus and Enterococci from Streptomyces sp. FJS31-2. Molecules 22(2):251Google Scholar
  27. Liu W, Christenson SD, Standage S, Shen B (2002) Biosynthesis of the enediyne antitumor antibiotic C-1027. Science 297(5584):1170–1173Google Scholar
  28. Li JS, Zhang H, Qi H et al. (2018) Bioactive naphthoquinone and anthrone derivatives from endophytic Micromonospora sp. NEAU-gq13. J Asian Nat Prod Res 26:1–10Google Scholar
  29. Li X, Zeng X, Sun J et al. (2014) Imperatorin induces Mcl-1 degradation to cooperatively trigger Bax translocation and Bak activation to suppress drug-resistant human hepatoma. Cancer Lett 348(1-2):146–155Google Scholar
  30. Lu C, Zhao Y, Jia WQ et al. (2017) A new anthracycline-type metabolite from Streptomyces sp. NEAU-L3. J Antibiot 70(10):1026–1028Google Scholar
  31. Luo X, Luo W, Lin C et al. (2014) Andrographolide inhibits proliferation of human lung cancer cells and the related mechanisms. Int J Clin Exp Med 7:4220–4225Google Scholar
  32. Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129(3):1261–1274Google Scholar
  33. Mei C, Zhou S, Zhu L et al. (2017) Antitumor effects of laminaria extract fucoxanthin on lung cancer. Mar Drugs 15(2):39Google Scholar
  34. Newman DJ, Cragg GM, Snader KM (2003) Natural products as sources of new drugs over the period 1981–2002. J Nat Prod 66:1022–1037Google Scholar
  35. Pan LL, Wang XL, Zhang QY et al. (2016) Boehmenan, a lignan from the Chinese medicinal plant Clematis armandii, induces apoptosis in lung cancer cells through modulation of EGF-dependent pathways. Phytomedicine 23(5):468–476Google Scholar
  36. Pinkhien T, Maiuthed A, Chamni S et al. (2016) Bishydroquinone renieramycin M induces apoptosis of human lung cancer cells through a mitochondria-dependent pathway. Anticancer Res 36(12):6327–6333Google Scholar
  37. Reyna DE, Garner TP, Lopez A et al. (2017) Direct activation of BAX by BTSA1 overcomes apoptosis resistance in acute myeloid leukemia. Cancer Cell 32(4):490–505Google Scholar
  38. Robles AI, Harris CC (2017) Integration of multiple “OMIC” biomarkers: a precision medicine strategy for lung cancer. Lung Cancer 107:50–58Google Scholar
  39. Shi H, Bi H, Sun X et al. (2018) Antitumor effects of tubeimoside-1 in NCI-H1299 cells are mediated by microRNA-126-5p-induced inactivation of VEGF-A/VEGFR-2/ERK signaling pathway. Mol Med Rep 17(3):4327–4336Google Scholar
  40. Son S, Ko SK, Jang M et al. (2017) Polyketides and anthranilic acid possessing 6-deoxy-α-l-talopyranose from a Streptomyces species. J Nat Prod 80(5):1378–1386Google Scholar
  41. Torre LA, Bray F, Siegel RL et al. (2015) Global cancer statistics, 2012. Cancer J Clin 65:87–108Google Scholar
  42. Trédan O, Galmarini CM, Patel K, Tannock IF (2007) Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99:1441–1454Google Scholar
  43. Wang CY, Bai XY, Wang CH (2014) Traditional Chinese medicine: a treasured natural resource of anticancer drug research and development. Am J Chin Med 42:543–559Google Scholar
  44. Wang M, Li Y, Shao M et al. (2014) Separation and phylogenetic analysis of actinomycetes with activity of against Candida albicans from Chishui danxia soil. J Zunyi Med Univ 37(4):404–408.Google Scholar
  45. Wang Y, Shao M, Yue C (2016) Research development of halogenated natural products derived microorganisms. J Zunyi Med Univ 39(4):435–440.Google Scholar
  46. Wei WT, Lin SZ, Liu DL, Wang ZH (2013) The distinct mechanisms of the antitumor activity of emodin in different types of cancer (Review). Oncol Rep 30(6):2555–2562Google Scholar
  47. Xu P, Cai X, Zhang W et al. (2016) Flavonoids of Rosa roxburghii Tratt exhibit radioprotection and anti-apoptosis properties via the Bcl-2(Ca2+)/Caspase-3/PARP-1 pathway. Apoptosis 21(10):1125–1143Google Scholar
  48. Yu P, Shi L, Song M, Meng Y (2017) Antitumor activity of paederosidic acid in human non-small cell lung cancer cells via inducing mitochondria-mediated apoptosis. Chem Biol Inter 269:33–40Google Scholar
  49. Zarogoulidis P, Petanidis S, Kioseoglou E et al. (2015) MiR-205 and miR-218 expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1 and Survivin in lung cancer cells. Cell Signal 27(8):1576–1588Google Scholar
  50. Zhou L, Wu F, Jin W et al. (2017) Theabrownin inhibits cell cycle progression and tumor growth of lung carcinoma through c-myc-related mechanism. Front Pharm 8:75Google Scholar
  51. Zhou R, Chen H, Chen J et al. (2018) Extract from Astragalus membranaceus inhibit breast cancer cells proliferation via PI3K/AKT/mTOR signaling pathway. BMC Complement Alter Med 18:83Google Scholar
  52. Zhu X, Jiang H, Li J et al. (2016) Anticancer effects of Paris saponins by apoptosis and PI3K/AKT Pathway in gefitinib-resistant non-small cell lung cancer. Med Sci Monit 22:1435–1441Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Wei Li
    • 1
  • Jie Zheng
    • 1
  • Wenhong Wang
    • 2
  • Zhongming Qian
    • 3
  • Yuxin Bao
    • 1
    • 4
    Email author
  1. 1.Research Center for Medicine & BiologyZunyi Medical UniversityZunyiChina
  2. 2.Guizhou Provincial College-based Key Lab for Tumor Prevention & Treatment with Distinctive MedicinesZunyi Medical UniversityZunyiChina
  3. 3.Laboratory of NeuropharmacologyFudan University School of PharmacyShanghaiChina
  4. 4.Center of Analysis & MeasurementZunyi Medical UniversityZunyiChina

Personalised recommendations